Track: CME Session
Track: Hybrid Session
Rana McKay, MD
UCSD
La Jolla, CA, United States
Disclosure(s): Contract Research: Bayer (Ongoing); Tempus (Ongoing)
Non-CE Consulting: AstraZeneca (Ongoing); Aveo (Ongoing); Bayer (Ongoing); BMS (Ongoing); Calithera (Ongoing); Caris (Ongoing); Dendreon (Ongoing); Exelixis (Ongoing); JNJ (Ongoing); Merck (Ongoing); Myovant (Ongoing); Novartis (Ongoing); Pfizer (Ongoing); Sanofi (Ongoing); Sorrento Therapeutics (Ongoing); Telix (Ongoing); Tempus (Ongoing)
Vignesh Packiam, MD
University of Iowa
Iowa City, Iowa, United States
Disclosure(s): No financial relationships to disclose
Daniel Shapiro, MD
University of Wisconsin-Madison
Disclosure(s): No financial relationships to disclose
Walter Stadler, MD
University of Chicago
Chicago, Illinois, United States
Disclosure(s): Consulting - Early phase drug development: Calico Life Sciences (Terminated, December 31, 2021)
Contract Research: Amgen (Ongoing); BMS (Ongoing); Calithera (Ongoing); Corvus (Ongoing); Merck (Ongoing); Pfizer (Ongoing); Roche/Genentech (Ongoing)
DSMB - bladder cancer: Astra-Zeneca (Ongoing)
DSMB - Phase 1: Treadwell Therapeutics (Ongoing)
DSMB - prostate cancer: Bayer (Ongoing); Merck (Ongoing); Pfizer (Ongoing)
Non-CE Consulting: Caremark/CVS (Ongoing); EMA Wellnes (Ongoing)
Speaker: Daniel Shapiro, MD – University of Wisconsin-Madison
Speaker: Vignesh T. Packiam, MD – University of Iowa
Speaker: Walter Stadler, MD – University of Chicago
Speaker: Rana McKay, MD – UCSD